Rosuvastatin: No Significant Benefit for Older Patients with Systolic Heart Failure: CORONA Study Results

AudioMedica News
AudioMedica News
Rosuvastatin: No Significant Benefit for Older Patients with Systolic Heart Failure: CORONA Study Results
Loading
/
Ake Hjalmarson
Ake Hjalmarson
Gordon Tomaselli
Gordon Tomaselli

REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
N Engl J Med 2007;357

AKE HJALMARSON, Sahlgrenska University, Göteborg
COMMENT: GORDON TOMASELLI, Johns Hopkins University, Baltimore

The lipid lowering agent rosuvastatin did not bring a significant benefit to older patients with systolic heart failure, according to the findings of the CORONA study released at the American Heart Association sessions in Orlando. Ake Hjalmarson talked with Peter Goodwin about the implications this has for using statins in older patients with heart failure.

[audio:https://www.audiomedica.com/podcasting/cardio/071105HjalmarsenTomaselliPODCAST.mp3]

Further reading

Sign up for AudioMedica.com news

* = required field
Speciality